SCHEMBL22365693

SCHEMBL22365693

CCCCNC(=S)CCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.45
EPHX1 P07099 4/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ACHE P22303 5/20 0.40
MMP2 P08253 1/20 0.40
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 2/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9879639 0.86 EPHX1 (0.50) CASP2EPHX1
SCHEMBL23736376 0.84
SCHEMBL28879783 0.82
SCHEMBL11176825 0.81 EPHX1 (0.52) CASP2EPHX1
SCHEMBL22365675 0.81 EPHX1 (0.52) CASP2EPHX1
SCHEMBL14957807 0.81 EPHX1 (0.52) CASP2EPHX1
SCHEMBL18248636 0.81 EPHX1 (0.52) CASP2EPHX1
SCHEMBL11309804 0.81 EPHX1 (0.52) CASP2EPHX1
SCHEMBL11318989 0.81 EPHX1 (0.52) CASP2EPHX1
SCHEMBL10731551 0.81 EPHX2 (0.49) EPHX1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108675938-B Novel method for preparing N-N-butylacrylamide 常州大学 2019-12-31 CN claimed
US-11813596-B2 Photocatalytic system and applications thereof Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-11-14 US disclosed
US-11813596-B2 Photocatalytic system and applications thereof Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-11-14 US disclosed
US-11813596-B2 Photocatalytic system and applications thereof Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-11-14 US disclosed
EP-3700910-B1 PHOTOCATALYTIC SYSTEM AND APPLICATIONS THEREOF MAX PLANCK GESELLSCHAFT (DE) 2022-08-03 EP disclosed
EP-3700910-B1 PHOTOCATALYTIC SYSTEM AND APPLICATIONS THEREOF MAX PLANCK GESELLSCHAFT (DE) 2022-08-03 EP disclosed
CN-106256175-B Resin composition for permanent insulation film, multilayer printed wiring board, and method for producing same 太阳油墨制造株式会社 2021-01-08 CN disclosed
US-20200290029-A1 PHOTOCATALYTIC SYSTEM AND APPLICATIONS THEREOF Max Planck Gesellschaft Zur Förderung Der Wissenschaften E.V (DE) 2020-09-17 US disclosed
US-20200290029-A1 PHOTOCATALYTIC SYSTEM AND APPLICATIONS THEREOF Max Planck Gesellschaft Zur Förderung Der Wissenschaften E.V (DE) 2020-09-17 US disclosed
EP-3700910-A1 PHOTOCATALYTIC SYSTEM AND APPLICATIONS THEREOF Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. (DE) 2020-09-02 EP disclosed
CN-108675938-B Novel method for preparing N-N-butylacrylamide 常州大学 2019-12-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200290029-A1 PHOTOCATALYTIC SYSTEM AND APPLICATIONS THEREOF HCCS, CRY1, PCBP1 CASP2 2375/4885EPHX1 2184/4885MEN1 4166/4885
US-11813596-B2 Photocatalytic system and applications thereof HCCS, CRY1, PCBP1 CASP2 2375/4885EPHX1 2184/4885MEN1 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.